South-Korea Gene Editing Market Size, Share,Trends, Growth Analysis Report, 2029

Overview Request Sample Pages Request Customization Download PDF

You are viewing: South Korea Gene Editing Market analysis

Part of: Gene Editing Market (Global)

The South Korea Gene Editing Market was valued at $22.9 Million in 2024 and projected to reach to $39 Million by 2029, representing a compound annual growth rate of 11.2%.

South Korea Gene Editing Market (2024-2029) : Size and Share

CAGR of

USD Million

South Korea Gene Editing Market Trends and Insights

This 11.2% compound annual growth rate reflects South Korea's strong commitment to biotechnology innovation and advanced healthcare infrastructure.
South Korea's position as a leading biotech hub in Asia Pacific is driving significant investment in gene editing technologies, including CRISPR and other precision medicine applications. The South Korea gene editing market benefits from government support, substantial R&D funding, and a highly skilled workforce in the life sciences sector.
South Korea's regulatory environment continues to evolve to accommodate emerging gene editing therapies, while academic institutions and private biotech firms collaborate on cutting-edge research.
Between 2024 and 2029, South Korea is expected to see increased adoption of gene editing in therapeutic development, diagnostics, and agricultural biotechnology applications..

Key Market Statistics

CAGR (2024-2029) 11.2% CAGR
Market Size, 2024 ~USD 22.9 Million
Forecast, 2029 ~USD 39 Million
Country South Korea

South Korea Gene Editing Market Overview

South Korea Gene Editing Market Dynamics

Related Ecosystem

Key Takeaways

South Korea's gene editing market is valued at $22.9 million in 2024 and is forecast to reach $39.0 million by 2029, representing an 11.2% CAGR.
South Korea's advanced biotech infrastructure and government R&D initiatives position it as a regional leader in gene editing innovation.
South Korea's regulatory framework is adapting to support clinical development and commercialization of gene editing therapies.
South Korea's market growth is driven by increasing investment from both public institutions and private biotech companies in precision medicine applications.

Gene Editing Market Report Scope

Report Metric	Details
Base Year	2024
Fastest Growing Segment	CROS & CDMOS (End User)
Forecast Period	2024�2029
Growth Rate	CAGR of 10.2% from 2024 to 2029
Largest Segment	PRODUCTS (Offering)
Market Size Base Year (Billions)	~USD 4.67 (2024)
Revenue Forecast (Billions)	~USD 7.59 (2029)
Segments Covered	Offering, Type, Technique, Technology, Application, End User

South Korea Gene Editing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

Products
Services

By Type

Cell Line Development & Engineering
Gene Editing Kits
Gene Editing Libraries
Gene Editing Reagents
Grna Synthesis & Vector Construction
Library Construction & Screening
Other Services
Reagents & Consumables
Software & Systems

By Technique

Gene Silencing
Knock-In
Knock-Out
Other Techniques

By Technology

Antisense
Base Editing
Crispr
Other Technologies
Rnai
Talens
Zfns

By Application

Cell Line Engineering
Drug Discovery & Development
Genome Editing
Other Applications

By End User

Academic & Research Institutes
Cros & Cdmos
Other End Users
Pharmaceutical & Biotechnology Companies

Target Audience

Key Companies in the South Korea Gene Editing Market

Company	HQ	Ownership	Strongest segments
EPPENDORF AG	Germany	Private Company	Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
ILLUMINA INC	United States	Public Company	Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
CALYXT	United States	Public Company	RTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects,
MAXCYTE, INC	United States	Public Company	ExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables,
BECKMAN COULTER	United States	Private Company	Clinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments,
TAKEDA PHARMACEUTICAL COMPANY	Japan	Public Company	Gastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone),
DANAHER CORPORATION	United States	Public Company	Biotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables),
REVVITY, INC.	United States	Public Company	Diagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms,
THERMO FISHER SCIENTIFIC INC.	United States	Public Company	Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAA	Germany	Public Company	Life Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
GENSCRIPT	Hong Kong	Public Company	Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
AGILENT TECHNOLOGIES, INC.	United States	Public Company	Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
LONZA	Switzerland	Public Company	Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
SANGAMO THERAPEUTICS	United States	Public Company	Hemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant),
PRECISION BIOSCIENCES	United States	Public Company	ARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243),
CELLECTIS S.A.	France	Public Company	Allogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue,
REGENERON PHARMACEUTICALS, INC.	United States	Public Company	EYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics),
TAKARA BIO INC.	Japan	Private Company	Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related),

EPPENDORF AG

Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.

ILLUMINA INC

Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.

CALYXT

Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.

MAXCYTE, INC

MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.

BECKMAN COULTER

Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.

DANAHER CORPORATION

Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

REVVITY, INC.

Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

MERCK KGAA

Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

GENSCRIPT

GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.

LONZA

Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.

SANGAMO THERAPEUTICS

Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.

PRECISION BIOSCIENCES

Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.

CELLECTIS S.A.

Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.

TAKARA BIO INC.

Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.

Reasons to Buy this Report

Frequently asked questions

What is the current size of South Korea's gene editing market?

South Korea's gene editing market was valued at $22.9 million in 2024 and is projected to grow to $39.0 million by 2029.

What is the expected growth rate for South Korea's gene editing market?

South Korea's gene editing market is expected to grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2029.

What factors are driving growth in South Korea's gene editing market?

South Korea's gene editing market growth is driven by government support for biotech R&D, a skilled scientific workforce, advanced healthcare infrastructure, and increasing clinical applications in precision medicine.

Which gene editing technologies are most prevalent in South Korea?

CRISPR-based technologies dominate South Korea's gene editing market, alongside other emerging platforms used in therapeutic development and diagnostic applications.

How is South Korea's regulatory environment supporting gene editing development?

South Korea's regulatory agencies are progressively updating guidelines to facilitate clinical trials and commercialization of gene editing therapies while maintaining safety and efficacy standards.

RESEARCH METHODOLOGY

This study on the gene editing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the gene editing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India). Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global gene editing market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global gene editing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing gene editing products and services; experts from the demand side, such as personnel from pharmaceutical & biotechnology companies, Academic & research institutes, and CROs & CDMOs. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

The key players in the industry and market have been identified through extensive secondary research.
The revenues generated from the gene editing market business of leading players have been determined through primary and secondary research.
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The gene editing market, as covered within the scope of this report, includes products, technologies, and services that facilitate genetic modifications across various applications. This encompasses reagents and consumables, as well as software and systems for planning, executing, and analyzing gene editing processes. Additionally, the report covers services that utilize gene editing technologies like CRISPR, TALEN, ZFN, and other methods such as Meganucleases, PiggyBac, and Prime Editing, applied in areas like cell line engineering, genome editing, drug discovery, clinical diagnostics, and xenotransplantation. These components serve end users, including pharmaceutical and biotechnology companies involved in therapeutic development, as well as academic and research institutes focused on scientific research.

Stakeholders

Manufacturers and distributors of gene editing products and services
Pharmaceutical and biotechnology companies
Market research and consulting firms
R&D centers
Researchers and scientists
Academic & research institutes
CDMOs & CROs
Biobanks
Diagnostic companies.

Report Objectives

To define, describe, segment, and forecast the gene editing market based on offerings, product type, product application, product technology, reagent & consumables technique, product end user, service type, service application, service end user and region
To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments concerning six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
To strategically profile the key players in the global gene editing market and comprehensively analyze their core competencies2 and market rankings.
To track and analyze competitive developments, such as product launches, acquisitions, collaborations, expansions, and partnerships in the gene editing market.
To profile the key players in the global gene editing market and comprehensively analyze their instruments, reagents, kits, consumables, and services portfolios, market positions, and core competencies
To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the gene editing market
To benchmark players within the gene editing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

Get the Full Gene Editing Market Report

Full forecast, segment splits, and company analysis for all Gene Editing Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)